In an effort to optimize the online experience of its customers, AnaSpec, a worldwide provider of integrated proteomics solutions, has moved its website to a faster, dedicated server. AnaSpec sales & marketing manager, Violeta Rajkovska, MBA, stated, “With the huge number of catalog products... - March 28, 2007 - AnaSpec, Inc.

Campaign for Baxa dedicated enteral systems focuses on educating providers on the risks, especially for neonatal patients, of wrong-route administration of non-IV fluids. While tubing misconnections can be deadly for any patient, neonates represent the highest risk population due to their small size and other health complications. The campaign launch closely follows the January 2007 release by the Joint Commission of their proposed 2008 National Patient Safety Goals (NPSGs) for comment. - March 21, 2007 - Baxa Corporation - Featured Press Release

Bio3 Research S.r.l., Milan – Italy, has been granted by the Australian Patent Office a patent in the field of cardiovascular diseases related to HMGB1 over-expression and for the use of HMGB1 protein in connective tissue regeneration. - March 16, 2007 - Bio3 Research S.r.l.

Two Colorado bioscience legislative initiatives are included in the national BIO “State Legislative Best Practices in Support of Bioscience Industry Development,” report issued late last year for state legislation promoting growth of bioscience clusters in 2005-06. Of the 23 standout initiatives, only two other states, California and Texas, had two projects highlighted. - March 14, 2007 - Colorado BioScience Association - Featured Press Release

AnaSpec, a worldwide provider of integrated proteomics solutions, announced today that the name of their flagship line of high-performance assay kits has been changed from EnzoLyte to SensoLyte™. AnaSpec sales & marketing manager, Violeta Rajkovska, MBA, noted, “The new name demonstrates... - March 14, 2007 - AnaSpec, Inc.

Xcelience's implementation of the CFS1200 will allow its formulation scientists the opportunity to accelerate the drug development timeframe. - March 13, 2007 - Xcelience, LLC

Xcelience achives its third successful audit. - March 09, 2007 - Xcelience, LLC

Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field. - March 05, 2007 - La Merie Business Intelligence

Four Colorado-based companies are participating at the 2007 Rocky Mountain Bioscience Venture Capital Meeting on the Mountain, March 2-4, at the Park City (UT) Marriott. Dorsey & Whitney, lead sponsor of the event, hosts venture capitalists and area companies to learn and explore bioscience opportunities in the Rocky Mountain Region. Co-sponsors include UV Partners, vSpring Capital and Wasatch Venture Fund. - March 04, 2007 - Colorado BioScience Association - Featured Press Release

XpertXchange will initiate dialogue between Xcelience scientists and drug development professionals. - March 02, 2007 - Xcelience, LLC

Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still No. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4%), and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25%). - February 27, 2007 - La Merie Business Intelligence

New Life Scientific, Inc. (OTCBB: NWLS), a company which specializes in the development of new biotechnology products and pharmaceuticals, announced today that it has transferred marketing rights to Atlan International(OTC: ATLI) of license agreement for two platform technologies (patent pending) that... - February 27, 2007 - New Life Scientific, Inc.

Nanion Technologies introduces the Internal Perfusion System for the Port-a-Patch; a completely unique device for rapid, continuous and automated exchange of internal solutions during patch clamp recordings. Using the internal perfusion system, ion channels regulated by internal binding sites for... - February 27, 2007 - Nanion Technologies GmbH

Colorado research institutions have begun reaping the rewards of legislation allocating state funds for bioscience research. HB 1360, sponsored by Representative Jim Reisberg (D-Greeley) and Senator Ron Tupa (D-Boulder), was signed into law by Governor Bill Owens last summer. $2 million in state funds was awarded to 27 bioscience proof of concept projects at six Colorado universities and research institutions. Initial reports are expected by the end of 2007. - February 23, 2007 - Colorado BioScience Association - Featured Press Release

Twenty-four Colorado-based companies exhibited at the 23rd annual Medical Device & Manufacturing (MD&M) West show in Anaheim, CA, February 13-15. Colorado has a strong medical device manufacturing sector and was well represented at the MD&M trade show and conference. Several of Colorado’s regional economic development agencies were also in Anaheim assisting exhibiting companies and promoting the State of Colorado as a great place for doing business. - February 16, 2007 - Colorado BioScience Association - Featured Press Release

HiTIS - life science & biotech intelligence, a global life sciences industry focused competitive intelligence firm, launched Skin Diseases Drug Development Weekly while the American Academy of Dermatology held its 65th annual meeting. - February 12, 2007 - HiTIS - Life Science & Biotech Intelligence

The Business Intelligence firm La Merie S.L. reported today that major diabetes companies are trying to keep pace with Eli Lilly and Amylin Pharmaceutical in the field of GLP-1 analogs to treat type 2 diabetes. Lilly’s and Amylin’s first-in-class, but twice-daily product exenatide posted... - February 06, 2007 - La Merie Business Intelligence

A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26. - February 05, 2007 - La Merie Business Intelligence

Pharma Trials International, Inc. a subsidiary of New Life Scientific, Inc. (OTCBB: NWLS), specializes in providing clinical trial services, market research, and services to enable pharmaceutical, biotech and medical device companies worldwide to conduct research and to obtain regulatory approval of... - February 01, 2007 - New Life Scientific, Inc.

Baxa Corporation announces the training schedule for its professional Skills Training, Academics and Resources (STAR) Center for pharmacy and cleanroom skills training. The STAR Center, a premier facility designed for cleanroom and pharmacy practice demonstration, is located at the company’s world headquarters south of Denver, Colorado. Baxa Corporation built the STAR Center to provide professional education on pharmacy practice, cleanroom principles and compliance to regulatory requirements. - January 22, 2007 - Baxa Corporation - Featured Press Release

LAMBDA Laboratory Instruments introduces a new digitally controlled, programmable powder dosing instrument. It allows precise, reproducible, automatic and continuous addition of powders, powdery and crystalline substances without a spoon. - January 20, 2007 - LAMBDA Laboratory Instruments

New catalog is magazine-catalog style and focuses on safety. Pharmacy safety enhancement has guided every Baxa innovation since their first product introduction more than 30 years ago. That product, the Exacta-Med® Oral Dispenser, has been the industry standard for safe administration of oral liquid medications ever since. - January 19, 2007 - Baxa Corporation - Featured Press Release

Baxa Corporation announces its agreement with VIASYS MedSystems to co-market a dedicated enteral feeding system for neonates that reduces catheter misconnection errors. The first syringes designed only for enteral feeding, Baxa Exacta-Med Enteral Syringes are available individually packaged in 20, 35 and 60 mL sizes. - January 18, 2007 - Baxa Corporation - Featured Press Release

The launch of Xpert Consulting will provide supplemental services to assist clients. - January 17, 2007 - Xcelience, LLC

A strongly growing market of now more than US$ 6 billion in 2006 for only two PPAR gamma agonists founds the basis for a heavily researched field of next generation mono, dual or triple PPAR agonists with fine-tuned subtype combinations. - January 12, 2007 - La Merie Business Intelligence

“Patient Safety and Peak Performance Through Pharmacy Training” from Baxa Corporation is now posted on PublicRelationsNewsroom.com for media and professional access. The article discusses the history of sterile compounding in pharmacy practice, current state, and the need for a purpose-built facility that provides practical, hands-on training in pharmacy preparation and regulatory compliance in order to achieve the level of patient safety and performance excellence required in today’s pharmacy. - December 28, 2006 - Baxa Corporation - Featured Press Release

At the annual conference of the American Society for Cell Biology, AnaSpec presented a technical poster documenting improved technology for MMP detection assays. In a previous poster, AnaSpec documented the use of highly sensitive FRET-peptide substrates for MMP detection. The latest poster documented... - December 19, 2006 - AnaSpec, Inc.

“Oral Medication Dispensers in Clinical Research,” a Technical Paper from Baxa Corporation is now posted for media and professional access on PublicRelationsNewsroom.com. Oral dispensers (syringes), long recognized as the safest and most accurate method to administer oral liquid medications, are especially valuable in clinical research where dosage accuracy has fundamental importance. - December 14, 2006 - Baxa Corporation - Featured Press Release

The substitution of the fluorine in place of hydrogen in building blocks, such as amino acids, has produced molecules with enhanced physiological activities (1-2). Some of these are antibacterial, antihypertensive and antitumoral (3). One reason for the enhanced activity is that fluorine forms a strong... - December 12, 2006 - AnaSpec, Inc.

Eric Kastango, president and CEO of Clinical IQ and frequent consultant to Baxa Corporation on hospital pharmacy safety issues is now profiled on the Expert Information For Journalists Web site – Expert411.com. Baxa Corp., a privately held company, is a leader in serving hospital pharmacy systems for handling, packaging and administering liquid medications from oral to multi-ingredient IV. Baxa is a registered medical device manufacturer with the FDA and has sales in more than 35 countries. - December 07, 2006 - Baxa Corporation - Featured Press Release

Baxa Corporation announces new syringe-type dispensers designed for enteral feeding only to prevent wrong-route administration of non-IV fluids. The new Baxa Exacta-Med® Enteral Dispensers feature a unique dispenser tip that cannot connect to a luer needle or needleless IV system. - December 05, 2006 - Baxa Corporation - Featured Press Release

Colorado-based pharmacy products manufacturer, Baxa Corporation, is sponsoring a program at the annual American Society of Health-System Pharmacists’ Midyear Clinical Meeting in Anaheim. The speaker will discuss basic facility requirements for USP 797 compliance and the challenge of integrating primary engineering controls into facilities. - December 04, 2006 - Baxa Corporation - Featured Press Release

Functional Genetics, Inc. announced today that it has received two different awards from the United States Defense Threat Reduction Agency for the discovery and development of therapeutics for Ebola virus and other viral pathogens. "These awards from DTRA will greatly assist our mission of discovering... - December 01, 2006 - Functional Genetics, Inc.

After very successful pre-clinical trials for its lead product ‘Minozac,’ Neuromedix is planning further work on this promising Alzheimer’s treatment. - December 01, 2006 - Neuromedix Inc.

Those seeking natural performance enhancement look to new technology that produces many of the same performance enhancing effects as steroids, EPO blood doping and high altitude / hypoxia training systems without the effort, cost or risks. - November 30, 2006 - EarthPulse Technologies, LLC

HiTIS - life science & biotech intelligence, a European life sciences industry focused competitive intelligence firm, recently launched Neurodegenerative Diseases Therapeutics & Diagnostics Competitive Intelligence Weekly - November 30, 2006 - HiTIS - Life Science & Biotech Intelligence

Los Angeles and Oslo based Gamma Medica Ideas, Inc. (GM-I), a leader in providing next-generation medical imaging devices for the pre-clinical and clinical markets, announced today that it had reached agreement to acquire and merge operations with Sherbrooke, Canada based Advanced Molecular Imaging,... - November 28, 2006 - Gamma Medica-Ideas

HiTIS - life science & biotech intelligence, a European life sciences industry- focused competitive intelligence firm, has released its corporate website. - November 23, 2006 - HiTIS - Life Science & Biotech Intelligence

HiTIS - life science & biotech intelligence, a life sciences industry focused competitive intelligence firm, has released the 26th weekly issue of its Eye Care industry competitive intelligence publication: Eye Therapies Competitive Intelligence Weekly (ETCI Weekly). - November 20, 2006 - HiTIS - Life Science & Biotech Intelligence

"USP 797 Training Requirements: A Case Study" published by Baxa Corporation is now posted for media and professional access on PublicRelationsNewsroom.com. This paper summarizes the process used by Swedish Medical Center in Seattle, WA to comply with the personnel training and evaluation in aseptic manipulation skills required by the United States Pharmacopeia (USP) Chapter 797. - November 16, 2006 - Baxa Corporation - Featured Press Release

Triangle-based specialty pharmaceutical company to serve $1.3 billion per year oral cephalosporin market - November 09, 2006 - Cornerstone BioPharma

New Exacta-Med Dispenser size provides another dosing option for oral liquid medications. Exacta-Med Oral Dispensers were the first syringes developed specifically for safe delivery of oral liquids. Baxa is the market leader for oral dispensing devices. - October 31, 2006 - Baxa Corporation - Featured Press Release

Study Results Show that Accurate in Vivo Quantitation of Drug Distribution and Therapeutic Effect is Possible and Important - October 26, 2006 - Gamma Medica-Ideas

Life science industry-focused competitive intelligence services practice adds outstanding orthopaedics expertise to founding team to develop new competitive intelligence periodical reports. - October 17, 2006 - HiTIS - Life Science & Biotech Intelligence

Gamma Medica-Ideas (GM-I) has been awarded a $100,000 grant to develop a SPECT/MRI small animal imaging system. The grant is part of an $850,000 fast-track grant award from the National Institutes of Health’s National Institute of Biomedical Imaging and Bioengineering. Dr. Douglas Wagenaar,... - October 05, 2006 - Gamma Medica-Ideas

Sleep is one of the most underestimated factors in athletic performance. Sleep deprived athletes have a reduced response time of up to 75% and fatigue related deficits can mean the difference between a medal or a loss. - September 25, 2006 - EarthPulse Technologies, LLC

Denver-based Baxa Corporation announces the signing of an exclusive co-marketing agreement with Unit Dose Solutions Inc. of Morrisville, NC. Under the agreement, Baxa will market and sell the oral unit dose repackaging services provided by Unit Dose Solutions. UDS serves hospital and alternate-care providers by offering an outsourcing alternative for unit dose packaging and labeling. - September 22, 2006 - Baxa Corporation - Featured Press Release

The anti-VEGF Fab Lucentis is the new standard of care to treat AMD because it can improve visual acuity. Competitor drugs directed against the same and innovative targets are applied with non-intravitreal forms of administration to avoid the unease of intra-vitreal injection. - September 20, 2006 - La Merie Business Intelligence

InViragen, LLC, a biotechnology company dedicated to developing vaccines for emerging infectious diseases worldwide, has entered into an Exclusive Patent License Agreement with the Centers for Disease Control and Prevention (CDC). The licensed technology is applicable to vaccines against multiple viral diseases, including dengue fever and West Nile disease. Dengue fever threatens 2.5 billion people worldwide as well as travelers to tropical countries. - September 14, 2006 - Colorado BioScience Association - Featured Press Release

Baxa Ltd, subsidiary of Denver-based Baxa Corporation, has moved to a direct sales and marketing model for the Austrian market. The company provides systems and devices for simplifying the handling, mixing and administration of fluid medications. Direct operations will provide Baxa Ltd with improved customer access for product development and continuous improvement, while continuing their excellent customer service. - September 12, 2006 - Baxa Corporation - Featured Press Release